Login to Your Account



Creabilis Raises $20M in Series B to Advance Psoriasis Drug

By Cormac Sheridan


Wednesday, October 5, 2011
Creabilis S.A. raised €15 million (US$20 million) in a Series B round to advance a pipeline of three compounds in development for dermatology, inflammation and pain indications. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription